<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02334163</url>
  </required_header>
  <id_info>
    <org_study_id>PHCL400</org_study_id>
    <nct_id>NCT02334163</nct_id>
  </id_info>
  <brief_title>The Effects of Nitazoxanide in Hepatic Encephalopathy</brief_title>
  <official_title>The Clinical Effects of Nitazoxanide in Hepatic Encephalopathy Patients: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Al-Azhar University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the efficacy and safety of nitazoxanide in comparison to standard treatment in
      patients with grade II-III hepatic encephalopathy (HE). Also, Evaluating the effect of
      administering nitazoxanide on the improvement of patient's quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nitazoxanide (NTZ) is a thiazolide anti-infective with activity against anaerobic bacteria,
      protozoa and viruses. A pilot prospective study at the 2008 American Association for the
      Study of Liver Diseases meeting showing clinical improvement in HE among cirrhotic patients
      who received nitazoxanide and lactulose. Based on the excellent safety profile of NTZ, the
      present pilot study is conducted hopefully to prove the efficacy of nitazoxanide in treating
      patients experiencing HE grade II-III.

      Study design:The study is Prospective, Randomized, Controlled, Open-Label, Pilot study.

      Method: The study will include a total of 36 patients with grade II-III Hepatic
      Encephalopathy, and an informed consent will be obtained from every patient before being
      included.

      All the patients will receive oral lactulose, plus either nitazoxanide, metronidazole or
      rifaximine.

      A- All patients will be subjected to the following at baseline:

        -  Patient's full history

        -  Liver disease staging using Model for End stage Liver Disease (MELD) score

        -  Measurement of serum electrolytes (Na+, K+, Ca2+)

      B- All patients will be subjected to the following at baseline and at the end of treatment:

        -  Measuring Blood ammonia level

        -  Measuring liver function tests (AST, Total bilirubin, international normalized ratio
           (INR), Serum albumin, prothrombin time (PT)), serum creatinine and complete blood count
           (CBC)

        -  Assessing severity of Hepatic Encephalopathy using Clinical Hepatic Encephalopathy
           Staging Scale (CHESS)

      C- Monitoring tolerability up to 30 days after the last dose D- Assessment of quality of life
      using Chronic Liver Disease Questionnaire (CLDQ)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating the efficacy of nitazoxanide in improving mental status (calculating CHESS score)</measure>
    <time_frame>7 days</time_frame>
    <description>evaluating the efficacy by measuring serum ammonia and calculating CHESS score at baseline and at end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluating the safety of nitazoxanide (estimation of treatment- related undesirable effects)</measure>
    <time_frame>37 days</time_frame>
    <description>Evaluating the safety of nitazoxanide by estimation of treatment- related undesirable effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of nitazoxanide on patient's quality of life (CLDQ score)</measure>
    <time_frame>7 days</time_frame>
    <description>Evaluating the effect on quality of life by calculating CLDQ score at baseline and at end of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Nitazoxanide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 patients will receive the following for 7 days:
Oral lactulose
500 mg nitazoxanide tablets twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 patients will receive the following for 7 days:
Oral lactulose
250 mg metronidazole tablets every 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifaximine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 patients will receive the following for 7 days:
Oral lactulose
Two 200 mg rifaximine tablets every 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>500 mg nitazoxanide tablets twice daily</description>
    <arm_group_label>Nitazoxanide group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral lactulose</intervention_name>
    <description>Oral lactulose (65%)</description>
    <arm_group_label>Nitazoxanide group</arm_group_label>
    <arm_group_label>Metronidazole group</arm_group_label>
    <arm_group_label>Rifaximine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>250 mg metronidazole tablets every 8 hours</description>
    <arm_group_label>Metronidazole group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximine</intervention_name>
    <description>Two 200 mg rifaximine tablets every 8 hours</description>
    <arm_group_label>Rifaximine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult Patients from 18 to 65 years.

          -  Patients with grade II-III Hepatic Encephalopathy.

        Exclusion Criteria:

          -  Patients with active GIT bleeding.

          -  Patients with major psychiatric illness.

          -  Patients receiving benzodiazepines, narcotics, alcohol and marijuana.

          -  Patients with compromised renal or biliary functions.

          -  Patients known to have AIDS.

          -  Patients receiving medications highly bound to plasma proteins eg. Warfarin.

          -  Patients with known hypersensitivity to nitazoxanide.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asmaa A. Elrakaybi, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amal T. Abd ElMoez, PhD</last_name>
    <email>d_amal_tohamy@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of medicine, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <zip>1156</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amal T. Abd ElMoez, PhD</last_name>
      <email>d_amal_tohamy@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Asmaa A. Elrakaybi, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2015</study_first_submitted>
  <study_first_submitted_qc>January 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2015</study_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Asmaa Abdel Aziz ElRakaybi</investigator_full_name>
    <investigator_title>Teaching assistant</investigator_title>
  </responsible_party>
  <keyword>Hepatic Encephalopathy</keyword>
  <keyword>Nitazoxanide</keyword>
  <keyword>Serum ammonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

